- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01035437
Study for Determination of Feasibility and Toxicity of Pre-Treatment With HPPH (2-1[1-Hexyloxyethyl]-2 Devinyl Pyropheophorbide-a) Photodynamic Therapy Prior to Chemoradiation in Non-Operable Patients With Obstructive Esophageal Cancer
June 28, 2012 updated by: Roswell Park Cancer Institute
A Pilot Study for Determination of Feasibility and Toxicity of Pre-Treatment With HPPH (2-1[1-Hexyloxyethyl]-2 Devinyl Pyropheophorbide-a) Photodynamic Therapy Prior to Chemoradiation in Non-Operable Patients With Obstructive Esophageal Cancer
This study aim is to find out what effects capecitabine, oxaliplatin and radiation therapy following photodynamic therapy have on esophageal cancer.
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Study Type
Interventional
Phase
- Not Applicable
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Partially or completely obstructing primary esophageal carcinoma, clinical stage I-IVa as determined by endoscopy, CT-scan, PET +/- endoscopic ultrasound. For distal esophagus tumors involving the GE junction, at least 50% or greater of the tumor bulk should be in the distal esophagus
- Ineligible for or refused surgical resection
- No Prior therapy allowed for esophageal cancer
- ECOG Performance status 0-1
- Life expectancy > 4 months
- Adequate hematologic parameters (hemoglobin> 9g/dl, ANC > 1500/ul, Platelets > 100,000/ul)
- Adequate biochemical parameters (total bilirubin and creatinine within institutional limits, AST and alkaline phosphatase less tham or equal to 3xUNL)
- Age > 18 years
- Signed informed consent
- Bronchoscopy with biopsy and cytology if primary esophageal cancer is < 26 cm from incisors
- Female patients of childbearing potential should have a negative serum or urine pregnancy test within 7 days prior to registration
- Patients of Childbearing potential agree to use an effective form of contraception during the study and for 90 days following the last dose of study medication (an effective form of contraception is an oral contraceptive or a double barrier method
- Both men and women and members of all races and ethnic are eligible for this trial
Exclusion Criteria:
- Hypersensitivity to platinum compounds, fluoropyrimidines or to antiemetics appropriate for administration in conjunction with protocol-directed chemotherapy
- Patients may not be receiving any other investigational agents
- Patients with known brain metastases should be excluded from this trail
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia or psychiatric illness/social situations that would limit compliance with study requirements
- Peripheral neuropathy ≥ Grade 2
- History of second malignancy within the previous years except for curatively treated carcinoma of the cervix in-situ or non-melanomatous skin cancer
- Patients who are pregnant or lactating
- Porphyria or hypersensitivity to porphyrin-like compounds
- Patients with known HIV or Hepatitis B or C (active, previously treated or both)
- Patients with tracheal or bronchial involvement, as determined by bronchoscopy
- Patients with documented unilateral or bilateral vocal cord paralysis
- Patients with T4 lesions by CT, MRI or EUS involving the aorta, lung or pericardium
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: HPPH
|
HPPH in D5W, 4.0 mg/m2 infused over 1 hour
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Determine the toxicity of sequential PDT and chemoradiation in obstructing esophageal cancer
Time Frame: 2 year
|
2 year
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Evaluate the efficacy of PDT in palliation of dysphagia
Time Frame: 2 years
|
2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2009
Primary Completion (ACTUAL)
January 1, 2011
Study Completion (ACTUAL)
February 1, 2011
Study Registration Dates
First Submitted
December 17, 2009
First Submitted That Met QC Criteria
December 17, 2009
First Posted (ESTIMATE)
December 18, 2009
Study Record Updates
Last Update Posted (ESTIMATE)
July 2, 2012
Last Update Submitted That Met QC Criteria
June 28, 2012
Last Verified
June 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- RPCI I 148809
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Esophageal Neoplasm
-
University Hospitals, LeicesterTerminatedEsophageal Neoplasm | Gastric NeoplasmUnited Kingdom
-
Mayo ClinicTerminatedEsophageal Cancer | Cancer of the Esophagus | Esophageal Neoplasm | Esophagus Cancer | Cancer of Esophagus | Neoplasm, Esophageal | Esophageal Neoplasms Malignancy Unspecified | Esophageal Neoplasms MalignantUnited States
-
University Hospital, LilleFederation of Research in Surgery (FRENCH); French Eso-Gastric Tumors Working... and other collaboratorsCompleted
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedGastroesophageal Junction Adenocarcinoma | Stage IIA Esophageal Cancer AJCC v7 | Stage IIB Esophageal Cancer AJCC v7 | Stage IIIA Esophageal Cancer AJCC v7 | Stage IIIB Esophageal Cancer AJCC v7 | Stage IIIC Esophageal Cancer AJCC v7 | Malignant Neoplasm of the Cervical Esophagus | Malignant Neoplasm...United States
-
Cancer Institute and Hospital, Chinese Academy...Peking University Cancer Hospital & InstituteRecruitingEsophageal Neoplasm Metastatic | Esophageal Cancer Stage IVbChina
-
Academisch Medisch Centrum - Universiteit van Amsterdam...RecruitingNeoplasm, Esophageal | Neoplasm, Esophagus | Malignant Esophagus TumorNetherlands
-
National Cancer Institute (NCI)RecruitingNeoplasms | Esophageal Neoplasms | Esophagus Cancer | Esophagus Neoplasm | Neoplasms, Esophageal | Esophageal Cancer (EsC)United States
-
Region SkaneTerminated
-
University Hospital, LilleRecruiting
-
Dr Kundan Singh ChufalActive, not recruitingEsophageal NeoplasmAustralia, India
Clinical Trials on HPPH 2-1[1-hexyloxyethyl]-2-devinyl Pyropheophorbide-a)
-
Johnson & Johnson Vision Care, Inc.Completed
-
Johnson & Johnson Vision Care, Inc.Completed
-
Marmara UniversityNot yet recruiting
-
University of Sao Paulo General HospitalCompletedOveractive Bladder SyndromeBrazil
-
Hanmi Pharmaceutical Company LimitedCompletedHypertensionKorea, Republic of
-
Yooyoung Pharmaceutical Co., Ltd.Active, not recruitingDyslipidemiasKorea, Republic of
-
University of PennsylvaniaHarvard University; Carnegie Mellon University; incentaHEALTH; McKinsey & CompanyCompleted
-
PfizerCompletedRheumatoid Arthritis | Healthy VolunteersUnited States
-
Coopervision, Inc.Completed
-
AstraZenecaAcerta Pharma, LLCCompletedBioavailability | B-cell Lymphoid CancerUnited States